Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Neuroblastoma Pipeline Drugs Market Overview
Neuroblastoma is a cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest, or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc.
The Neuroblastoma pipeline market research report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.
Neuroblastoma Pipeline Products Market Segmentation by Targets
The key targets in the Neuroblastoma pipeline products market are Cells Expressing Ganglioside GD2, Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein, ALK Tyrosine Kinase Receptor, Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I, Programmed Cell Death Protein 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Vascular Endothelial Growth Factor Receptor 2, and others.
Neuroblastoma Pipeline Products Market Analysis by Targets
For more target insights into the Neuroblastoma pipeline products market, download a free report sample
Neuroblastoma Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Neuroblastoma pipeline products market are Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, Cytotoxic To Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic To Cells Expressing Neural Cell Adhesion Molecule 1, and others.
Neuroblastoma Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Neuroblastoma pipeline products market, download a free report sample
Neuroblastoma Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Neuroblastoma pipeline products market are intravenous, oral, parenteral, intraperitoneal, subcutaneous, intratumor, intrathecal, intracerebral, intradermal, intraarterial, and others.
Neuroblastoma Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Neuroblastoma pipeline products market, download a free report sample
Neuroblastoma Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Neuroblastoma pipeline products market are small molecule, gene-modified cell therapy, monoclonal antibody, monoclonal antibody conjugated, oncolytic virus, synthetic peptide, cell therapy, antisense RNAi oligonucleotide, aptamer, conjugate vaccine, and others.
Neuroblastoma Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Neuroblastoma pipeline products market, download a free report sample
Neuroblastoma Pipeline Products Market - Competitive Landscape
Some of the leading companies in the Neuroblastoma pipeline products market are Y-mAbs Therapeutics Inc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, PersonGen BioTherapeutics (Suzhou) Co Ltd, Pfizer Inc, SMTPH Ltd, Advanced Accelerator Applications SA, Advenchen Laboratories LLC, and AstraZeneca Plc.
Neuroblastoma Pipeline Products Market Analysis by Companies
To know more about the leading players in the Neuroblastoma pipeline products market, download a free report sample
Neuroblastoma Pipeline Products Market Report Overview
Key Targets | Cells Expressing Ganglioside GD2, Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein, ALK Tyrosine Kinase Receptor, Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I, Programmed Cell Death Protein 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Vascular Endothelial Growth Factor Receptor 2, and Others |
Key Mechanisms of Action | Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, Cytotoxic To Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic To Cells Expressing Neural Cell Adhesion Molecule 1, and Others |
Key Routes of Administration | Intravenous, Oral, Parenteral, Intraperitoneal, Subcutaneous, Intratumor, Intrathecal, Intracerebral, Intradermal, Intraarterial, and Others |
Key Molecule Type | Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Oncolytic Virus, Synthetic Peptide, Cell Therapy, Antisense RNAi Oligonucleotide, Aptamer, Conjugate Vaccine, and Others |
Leading Companies | Y-mAbs Therapeutics Inc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, PersonGen BioTherapeutics (Suzhou) Co Ltd, Pfizer Inc, SMTPH Ltd, Advanced Accelerator Applications SA, Advenchen Laboratories LLC, and AstraZeneca Plc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Actuate Therapeutics Inc
ADC Therapeutics SA
Adicet Bio Inc
Advanced Accelerator Applications SA
Advanced Innovative Partners Inc
Advenchen Laboratories LLC
Alaunos Therapeutics Inc
Alissa Pharma
Aptorum Group Ltd
Arromax Pharmatech Co Ltd
Ascentage Pharma Group International
AstraZeneca Plc
Athenex Inc
AUM Biosciences Pte Ltd
Autolus Therapeutics Plc
Bayer AG
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
Biocad
BioEclipse Therapeutics Inc
Biogenera SpA
BioLineRx Ltd
Biosceptre International Ltd
Bristol-Myers Squibb Co
Cebiotex SL
Cellectar Biosciences Inc
Chiome Bioscience Inc
Clarity Pharmaceuticals Ltd
Collaborations Pharmaceuticals Inc
CorMedix Inc
Cothera Bioscience Pty Ltd
Curis Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DeepCure Inc
DEKK-TEC Inc
DOSE Therapeutics Inc
Edison Oncology Holding Corp
Eli Lilly and Co
Epigene Therapeutics Inc
Epizyme Inc
Exelixis Inc
Expression Therapeutics Inc
F. Hoffmann-La Roche Ltd
GAiA BioMedicine Inc
Gate2Brain SL
Gibson Oncology LLC
GSK plc
Helixmith Co Ltd
Innovent Biologics Inc
Invenra Inc
Ipsen SA
Jubilant DraxImage Inc
KC Pharma LLC
Lantheus Holdings Inc
Lead Discovery Center GmbH
LegoChem Biosciences Inc
MacroGenics Inc
Mana Therapeutics Inc
MediaPharma SRL
Merck & Co Inc
Nanjing CART Medical Technology Co Ltd
Nanogenics Ltd
NanoPharmaceuticals LLC
Nektar Therapeutics
Novartis AG
NovoMedix LLC
Nurix Therapeutics Inc
Nuvalent Inc
OBI Pharma Inc
OGD2 Pharma SAS
Oncolys BioPharma Inc
Onconova Therapeutics Inc
OncoTherapy Science Inc
Ono Pharmaceutical Co Ltd
Open Therapeutics LLC
Orgenesis Inc
Orphelia Pharma SAS
Panbela Therapeutics Inc
Peel Therapeutics Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Progenics Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
PYC Therapeutics Ltd
Qualigen Therapeutics Inc
Recombio SL
Recordati SpA
Ribomic Inc
Rophibio Inc
San Rocco Therapeutics LLC
Sapience Therapeutics Inc
SciTech Development LLC
Secura Bio Inc
Seneca Therapeutics Inc
Senhwa Biosciences Inc
Shionogi & Co Ltd
SignalRx Pharmaceuticals Inc
Sinobioway Cell Therapy Co Ltd
SMTPH Ltd
Sorrento Therapeutics Inc
Statera Biopharma Inc
Stemsynergy Therapeutics Inc
T-Cure Bioscience Inc
Tactiva Therapeutics LLC
TC BioPharm Ltd
Tmunity Therapeutics Inc
Toko Pharmaceutical Industries Co Ltd
Trellis Bioscience Inc
TroBio Therapeutics Pty Ltd
UGISense AG
UTC Therapeutics Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Xcovery Holding Co LLC
Y-mAbs Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Neuroblastoma pipeline products market?
The key targets in the Neuroblastoma pipeline products market are Cells Expressing Ganglioside GD2, Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein, ALK Tyrosine Kinase Receptor, Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I, Programmed Cell Death Protein 1, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Vascular Endothelial Growth Factor Receptor 2, and others.
-
What are the key mechanisms of action in the Neuroblastoma pipeline products market?
The key mechanisms of action in the Neuroblastoma pipeline products market are Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing CD276 Antigen, N Myc Proto Oncogene Protein Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, Cytotoxic To Cells Expressing ALK Tyrosine Kinase Receptor, DNA Topoisomerase I Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Cytotoxic To Cells Expressing Neural Cell Adhesion Molecule 1, and others.
-
What are the key routes of administration in the Neuroblastoma pipeline products market?
The key routes of administration in the Neuroblastoma pipeline products market are intravenous, oral, parenteral, intraperitoneal, subcutaneous, intratumor, intrathecal, intracerebral, intradermal, intraarterial, and others.
-
What are the key molecule types in the Neuroblastoma pipeline products market?
The key molecule types in the Neuroblastoma pipeline products market are small molecule, gene-modified cell therapy, monoclonal antibody, monoclonal antibody conjugated, oncolytic virus, synthetic peptide, cell therapy, antisense RNAi oligonucleotide, aptamer, conjugate vaccine, and others.
-
Who are the leading players in the Neuroblastoma pipeline products market?
The leading companies in the Neuroblastoma pipeline products market are Y-mAbs Therapeutics Inc, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, Novartis AG, PersonGen BioTherapeutics (Suzhou) Co Ltd, Pfizer Inc, SMTPH Ltd, Advanced Accelerator Applications SA, Advenchen Laboratories LLC, and AstraZeneca Plc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.